Portfolio Companies News
December 14, 2017WTX101 granted Fast Track designati...
Dec 14, 2017 Wilson Therapeutics AB (publ), today announced that the U.S. Food and Drug Administration (FDA) has granted WTX101 Fast Track designation for the treatment of Wilson Disease. The FDA’s Fast Track program is designed to facilitate the development, and expedite the review of novel th... read more
December 13, 2017Strongbridge Biopharma plc Added to...
DUBLIN, Ireland and TREVOSE, Pa., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, announced today that i... read more
December 13, 2017BONESUPPORT™ ACHIEVES AIM OF RECR...
Lund, Sweden, 08.00 CET, 13 December 2017 – BONESUPPORTTM, an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT® platform today announces that it has achiev... read more
December 12, 2017Orexo discloses more information ab...
Uppsala, Sweden – December 12, 2017 - Orexo AB today announces specific information about the improved market access position for Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) in the US effective January 1, 2018, and previously announced in the Interim Report for the third qua... read more
December 11, 2017HealthTech company Doctrin raises S...
HealthTech company Doctrin raises SEK 100 million in a Series A round led by healthcare provider Capio and Life Science fund HealthCap, with Inbox Capital and Norrsken Foundation as co-investors. The investment enables Doctrin to accelerate expansion in Sweden and internationally, as well as f... read more
November 13, 2017Q3 2017 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
24 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.